Football Association of Wales (FAW) chief executive Noel Mooney has revealed the "legacy" role of Wrexham owners Ryan ...

Ryan Reynolds and Rob McElhenney have never been shy about big dreams for Wrexham. From Hollywood screens to the oldest ...

Ryan Reynolds and Rob McElhenney's ambitious plans for Wrexham's SToK Cae Ras home could see World Cup 2035 games played at ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Stoke Therapeutics (STOK) to $28 from $29 and keeps a Buy rating on the shares. The ...

Phil Parkinson's side are aiming to sign a 27-year-old from Bournemouth, while they are also keen on Liverpool, Cardiff and ...

Manager Phil Parkinson says the arrival of three Wales internationals at the Stok Cae Ras shows the progress Wrexham have ...

Wrexham smashed its club record for a transfer fee in announcing the signing of Nathan Broadhead from Ipswich Town on ...

Wrexham have broken their transfer record in a deal worth up to £10million for Ipswich striker Nathan Broadhead. The 27-year-old Wales international has signed a four-year contract at SToK Cae Ras ...

Wrexham take on West Bromwich this Saturday at the STOK Cae Ras (The Racecourse Ground) in the matchweek two of the EFL ...

The lawsuit claims that Chobani is free-riding on Danone’s brand equity and marketing investment in RTD coffee by copying ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.